Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 6/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25026381 | 0.89 | ACACB (0.51) | NR1H2ACACBGPR119CYP11B2RET | |
| SCHEMBL20029227 | 0.82 | MAPT (0.53) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL31640018 | 0.81 | EGLN2 (0.48) | NR1H2EGLN2ACACBGPR119CYP11B2 | |
| SCHEMBL25025017 | 0.79 | NR1H2 (0.45) | NR1H2GPR119 | |
| SCHEMBL31053859 | 0.79 | NR1H2 (0.45) | NR1H2GPR119 | |
| SCHEMBL25027043 | 0.79 | ACACB (0.43) | ACACBGPR119CYP11B2 | |
| SCHEMBL20510344 | 0.78 | CYP2C9 (0.53) | EGLN2GPR119CYP11B2ALDH1A1 | |
| SCHEMBL24753076 | 0.78 | CKS1B (0.51) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL13015636 | 0.78 | CYP11B2 (0.46) | NR1H2EGLN2ACACBGPR119CYP11B2 | |
| SCHEMBL10111760 | 0.78 | GPR119 (0.59) | EGLN2GPR119CYP11B2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |